France· FR:66615713
TERCIAN 40 mg/ml, solution buvable en gouttes
A cyamemazine product containing cyamémazine, registered in France by ATNAHS PHARMA FRANCE, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CYAMÉMAZINE
- Manufacturer
- ATNAHS PHARMA FRANCE
- Country
- France (FR)
- ATC code
- N05AA06
- ATC class
- Cyamemazine
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009313032991 flacon(s) en verre brun de 30 ml avec seringue(s) doseuse(s)EUR 5.02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under N05AA06
Cyamemazine, as other registers publish it.
- FranceCYAMEMAZINE ARROW 100 mg, comprimé pelliculé sécableARROW GENERIQUES
- FranceCYAMEMAZINE ARROW 25 mg, comprimé pelliculé sécableARROW GENERIQUES
- FranceCYAMEMAZINE BIOGARAN 100 mg, comprimé pelliculé sécableBIOGARAN
- FranceCYAMEMAZINE BIOGARAN 25 mg, comprimé pelliculé sécableBIOGARAN
- FranceCYAMEMAZINE VIATRIS 100 mg, comprimé pelliculé sécableVIATRIS SANTE
- FranceCYAMEMAZINE VIATRIS 25 mg, comprimé pelliculé sécableVIATRIS SANTE
- FranceTERCIAN 100 mg, comprimé pelliculé sécableATNAHS PHARMA FRANCE
- FranceTERCIAN 50 mg/5 ml, solution injectable en ampouleATNAHS PHARMA FRANCE
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Portugal · Ciamemazina Generis, Tercian
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/671aee58-9c3c-4c56-8509-b82da2d4c3af GET /v1/drugs/671aee58-9c3c-4c56-8509-b82da2d4c3af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66615713",
"date_amm": "1988-07-27",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CYAMÉMAZINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution buvable en gouttes",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about cyamemazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.